UnitedHealth Group Incorporated (NYSE:UNH) Shares Sold by Castle Rock Wealth Management LLC

Castle Rock Wealth Management LLC reduced its position in UnitedHealth Group Incorporated (NYSE:UNH) by 72.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 713 shares of the healthcare conglomerate’s stock after selling 1,861 shares during the quarter. Castle Rock Wealth Management LLC’s holdings in UnitedHealth Group were worth $373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NewSquare Capital LLC bought a new stake in UnitedHealth Group in the fourth quarter valued at about $25,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in UnitedHealth Group in the fourth quarter valued at about $26,000. Hurley Capital LLC bought a new stake in UnitedHealth Group in the fourth quarter valued at about $28,000. Aster Capital Management DIFC Ltd acquired a new position in UnitedHealth Group in the fourth quarter valued at approximately $30,000. Finally, Promus Capital LLC acquired a new stake in shares of UnitedHealth Group during the 4th quarter worth approximately $32,000. 87.86% of the stock is owned by institutional investors.

UnitedHealth Group Stock Down 0.2%

Shares of UnitedHealth Group stock opened at $294.99 on Wednesday. The stock’s fifty day moving average is $443.90 and its 200-day moving average is $500.04. The firm has a market capitalization of $267.60 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.56. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74. UnitedHealth Group Incorporated has a 12-month low of $248.88 and a 12-month high of $630.73.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Thursday, April 17th. The healthcare conglomerate reported $7.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.29 by ($0.09). The company had revenue of $109.58 billion for the quarter, compared to analyst estimates of $111.56 billion. UnitedHealth Group had a return on equity of 26.69% and a net margin of 3.60%. During the same period last year, the firm earned $6.91 earnings per share. Equities analysts anticipate that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

Insider Activity

In other UnitedHealth Group news, CEO Stephen J. Hemsley purchased 86,700 shares of the company’s stock in a transaction that occurred on Friday, May 16th. The shares were purchased at an average cost of $288.57 per share, with a total value of $25,019,019.00. Following the completion of the transaction, the chief executive officer now owns 679,493 shares of the company’s stock, valued at approximately $196,081,295.01. This represents a 14.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Timothy Patrick Flynn purchased 1,533 shares of the company’s stock in a transaction that occurred on Wednesday, May 14th. The shares were acquired at an average cost of $320.80 per share, for a total transaction of $491,786.40. Following the completion of the transaction, the director now directly owns 6,033 shares of the company’s stock, valued at $1,935,386.40. This trade represents a 34.07% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 109,408 shares of company stock worth $31,607,768. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UNH shares. Mizuho reduced their price objective on UnitedHealth Group from $515.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, May 16th. Bank of America lowered UnitedHealth Group from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $560.00 to $350.00 in a research report on Wednesday, May 14th. Robert W. Baird reduced their price objective on UnitedHealth Group from $510.00 to $356.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Wolfe Research reduced their price objective on UnitedHealth Group from $501.00 to $390.00 and set an “outperform” rating for the company in a research report on Tuesday, May 20th. Finally, Truist Financial reiterated a “buy” rating and set a $360.00 price target (down previously from $580.00) on shares of UnitedHealth Group in a research report on Monday, May 19th. One analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, UnitedHealth Group currently has an average rating of “Moderate Buy” and a consensus target price of $441.87.

UnitedHealth Group Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.